Table 1

Properties of the K. pneumoniae strains isolated from the patient and of the pKPN101-IT-transformed and untransformed laboratory E. coli strainsa

Isolate typebSample type(s)Place of isolationDate of isolation (day.mo.yr)STMIC (mg/liter)Antimicrobial therapy
CTXCAZIPMMEMTGCCST
K. pneumoniaeUrine, BAL fluidFlorence21.05.2011≥64≥64≥16≥162≤0.5Colistin (480 mg/day), tigecycline (100 mg/day), and rifampin (600 mg/day) for 20 days
K. pneumoniaeBAL fluidPadua28.06.2011–19.07.2011101≥64≥64≥16≥162≤0.5Colistin (480 mg/day), tigecycline (60 mg/day), and rifampin (600 mg/day) for 30 days
Non-K. pneumoniae non-MDR strainsUrine, BAL fluid, blood, perirectal swabs, catheters, liquorPadua27.07.2011–22.08.2011NANANANANANANAMeropenem (4 g/day) and trimethoprim-sulfamethoxazole (240 and 1,200 mg/day, respectively) for 10 days
K. pneumoniaePerirectal swabPadua23.08.2011–20.09.2011101≥64≥64≥16≥162≤0.5Colistin (480 mg/day) and tigecycline (150 mg/day) for 20 days
Non-K. pneumoniae non-MDR strainsUrine, blood, perirectal swabs, liquor, sputumPadua21.09.2011–13.10.2011NANANANANANANAMeropenem (4 g/day) and trimethoprim-sulfamethoxazole (240 and 1,200 mg/day, respectively) for 15 days
E. coli TOP10 pKPN101-ITColonyNANANA416≥16≥16≤0.5≤0.5NA
E. coli TOP10 wild typeColonyNANANA≤1≤1≤1≤0.25≤0.5≤0.5NA
  • a CTX, cefotaxime; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; TGC, tigecycline; CST, colistin; NA, not applicable; –, not available.

  • b E. coli TOP10 is a laboratory strain transformed with pKPN101-IT.